Abstracts tagged "prognostic factors"

Abstract Number: 0490 • ACR Convergence 2020
Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁴, Ritu Gill⁶, Hiroto Hatabu⁷, Mizuki Nishino⁷, Cynthia Crowson⁸, John Davis¹, William Robinson⁹, Tripta Rughwani⁹, Jeremy Sokolove¹⁰, Michael Weinblatt⁴, Nancy Shadick¹¹, Tracy J. Doyle¹² and Jeffrey Sparks¹¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Department of Radiology; Brigham and Women’s Hospital, Boston, ⁸Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Mountain View, CA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹²Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical…
Abstract Number: 1763 • ACR Convergence 2020
Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
Robert Landewé¹, Daniel H Solomon², Gianluca Bonfanti³, Luigi Manca³, John C Woolcott⁴, Jasper Deuring⁵, Stephen Watt⁶, Pritha Bhadra Brown⁶, Rebecca Germino⁶, Birol Emir⁶ and Roger A Edwards⁷, ¹Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³Fair Dynamics Consulting, SRL, Milan, Italy, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Rotterdam, Netherlands, ⁶Pfizer Inc, New York, NY, ⁷Health Services Consulting Corporation, Boxborough, MA
Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus…
Abstract Number: 0637 • ACR Convergence 2020
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
Benjamin Naovarat¹, Francis Williams¹ and John Reveille², ¹The University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
Abstract Number: 1803 • ACR Convergence 2020
Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to Characterize Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohort of SLE Patients
Melissa Munroe¹, Wade DeJager², Susan Macwana², Ly Tran², Joel Guthridge², Eldon Jupe³, Daniele DeFreese³, Ryan Newhardt³, Mohan Purushothaman³, Sanjiv Sharma³, Nancy Redinger², Teresa Aberle², Stan Kamp², Cristina Arriens², Eliza Chakravarty², Joan Merrill⁴ and Judith James⁵, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease driven by complex immune dysregulation, involving altered immune mediators and accumulation of autoantibody (AutoAb) specificities.…
Abstract Number: 0648 • ACR Convergence 2020
Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis
Sally Stauder¹ and Paul Peloso², ¹Tulane University, Ponte Vedra Beach, FL, ²Horizon Therapeutics plc, Gurnee, IL
Background/Purpose: Dual Energy CT Scan (DECT) can detect monosodium urate crystals in joints and periarticular tissues. EULAR gout guidelines (Richette, 2020) recognized DECT's value in…
Abstract Number: 1807 • ACR Convergence 2020
The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis
Sang Jin Lee¹, Eon Jeong Nam¹, Man-Hoon Han² and Yong Jin Kim², ¹Department of Internal Medicine, Kyungpook National University Hospital,, Daegu, Republic of Korea, ²Department of Pathology, Kyungpook National University Hospital,, Daegu, Republic of Korea
Background/Purpose: Lupus nephritis is common clinical manifestation and contributes significantly to mortality in systemic lupus erythematosus (SLE). Recently several studies has been reported that severity of…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 0753 • ACR Convergence 2020
Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
Stéphanie de Montjoye¹, Tatiana Sokolova¹, Emilie Sapart¹, Bernard Lauwerys², Stéphanie Dierckx³, Christine Galant⁴, Laurent Meric de Bellefon¹, Adrien Nzeusseu Toukap⁵, Clément Triaille⁶ and Patrick Durez⁷, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ⁴3Pathology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁵1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…
Abstract Number: 1901 • ACR Convergence 2020
Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study
Rikke Asmussen Andreasen¹, Xenofon Baraliakos², Lars Erik Kristensen³, Kenneth Egstrup⁴, Vibeke Strand⁵, Hans Christian Horn⁶, Jimmi Wied⁶, Berit Schiøttz-Christensen⁷, Claus Aalykke¹, Inger Marie Hansen¹, Torkell Juulsgaard Ellingsen⁸ and Robin Christensen⁹, ¹Odense University Hospital, Svendborg, Svendborg, Denmark, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Odense University Hospital Svendborg, Svendborg, Denmark, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Odense University Hospital, Odense, Denmark, ⁷Spine Centre of Southern Denmark. Hospital lillebaelt, Middelfart, Denmark, ⁸Rheumatology Research Unit, Dept of Rheumatology Odense University Hospital, Odense C, Denmark, ⁹Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark
Background/Purpose: Despite better control of inflammation, many patients with axial spondyloarthritis (axSpA) still report pain, although they could be in remission. This suggests that in…
Abstract Number: 0015 • ACR Convergence 2020
COVID -19 Lung Inflammation – What Have We Learnt so Far ?
Sriya Gokaraju¹, Maria Darda², Vinod Vijayaraghavan Nalini Warrier³, Irina Duta³, Fiona Hayes³, Yasser Ahmed⁴ and Gouri Koduri³, ¹Southend University Hospital NHS Trust, Essex, United Kingdom, ²Southend University Hospital NHS Trust, Essex, United Kingdom, ³Southend University Hospital NHS Trust, Essex, United Kingdom, ⁴Southend University Hospital, Essex, United Kingdom
Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…
Abstract Number: 0766 • ACR Convergence 2020
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Rodrigo Garcia Salinas¹, Alvaro Ruta¹, Santiago Ruta¹, Einer Sanchez Prado¹, Jessica Torres Chichande¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: Autoantibody positivity, erosions, activity level, and functional capacity were classically defined as poor prognosis. Paradoxically, many of them also predict a good response to…
Abstract Number: 1968 • ACR Convergence 2020
Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Elena Tchetina¹, Kseniya Glemba¹, Galina Markova¹, Maksim Makarov¹ and Aleksandr Lila¹, ¹Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Osteoarthritis (OA) is a chronic rheumatic disease, which involves pain, limited inflammation, and local destruction of the knee joint. OA pain is a major…
Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Alberta Hoi ¹, Hieu Nim ², Rachel Koelmeyer ², Ying Sun ³, Amy Kao ⁴, Oliver Guenther ³ and Eric Morand², ¹School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Merck Healthcare KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc., Billerica, MA
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…
Abstract Number: 2012 • 2019 ACR/ARP Annual Meeting
A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients
Peter Taylor¹, Bryan Downie ², Emon Elboudwarej ³, Rachael Hawtin ³, Amer M. Mirza ³ and Jinfeng Liu ³, ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster Citty, CA, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].